510(k) device
FreeStyle Libre 3 Continuous Glucose Monitoring System
Abbott Diabetes Care, Inc. · Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ, Class II) · First FDA decision Apr 13, 2023, newest Apr 23, 2024Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
65
Naming "FreeStyle Libre 3"
MAUDE reports
264,959
Brand "FreeStyle Libre 3", since 2015
PubMed studies
33
Mentioning "FreeStyle Libre 3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FreeStyle Libre 3 Continuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K223435 · Decided Apr 13, 2023 · 150 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "FreeStyle Libre 3", any status and sponsor, newest update first.
- Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.Pivotal-lookingActive, not recruiting
Australian Catholic UniversityAcademic, hospital or other
NCT06888687 · 160 participants · Start May 12, 2025 · Primary completion Nov 28, 2026
Device: Continuous glucose monitoring · For: Type 2 Diabetes Mellitus (T2DM); Continuous Glucose Measurement; Dietary Modification
Sites: Melbourne, Australia
IMDEA FoodAcademic, hospital or other
NCT07626658 · 471 participants (planned) · Start Oct 15, 2026 · Primary completion May 2028
Device: Continuous glucose monitoring using a wearable sensor (flash interstitial glucose monitor) · For: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance); Artificial Intelligence Mobile Application
Sites: Madrid, Spain
- Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With DiabetesNot yet recruiting
University of the PacificAcademic, hospital or other
NCT07920341 · 60 participants (planned) · Start Nov 4, 2026 · Primary completion Nov 4, 2027
Device: FreeStyle Libre 3 Plus Continuous Glucose Monitor · For: Continuous Glucose Monitoring; Type 1 Diabetes; Type 2 Diabetes
Sites: Stockton, California
62 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FreeStyle Libre 3", and for the whole product code for context.
This brand
264,959 reports: 246,408 malfunction, 18,371 injury, 96 death
Whole product code QBJ
2,390,871 reports: 2,344,654 malfunction, 45,370 injury, 256 death
Newest reports for this brand
- FreeStyle Libre 3 PlusMalfunction
2954323-2026-448743 · Received Oct 30, 2026 · Event dated Oct 19, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Device Alarm System
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- FreeStyle Libre 3 PlusMalfunction
2954323-2026-448746 · Received Oct 30, 2026 · Event dated Oct 4, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- FreeStyle Libre 3 PlusMalfunction
2954323-2026-448747 · Received Oct 30, 2026 · Event dated Oct 5, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1021-2026 · Started Nov 24, 2025 · Posted by FDA Jan 14, 2026
Reason given: Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Cause as FDA categorized it: Process control · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems (QLG)
Z-1022-2026 · Started Nov 24, 2025 · Posted by FDA Jan 14, 2026
Reason given: Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Cause as FDA categorized it: Process control · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems (QLG)
Published research
The most relevant PubMed records for "FreeStyle Libre 3"[tiab]. The summary above synthesizes these.
- FreeStyle Libre 3.
Nguyen A, White JR · Clin Diabetes · 2022
- Accuracy of the Freestyle Libre 3 Continuous Glucose Monitoring System in Hypo- and Euglycemic Cats.
Tardo AM, Crews C, Mott J, et al. · J Vet Intern Med · 2025
- Evaluation of the FreeStyle Libre 3 in client-owned diabetic cats.
Tardo AM, Del Baldo F, Bonzagni S, et al. · J Vet Intern Med · 2026
- A Comparative Analysis of Glycemic Metrics Derived From Three Continuous Glucose Monitoring Systems.
Freckmann G, Wehrstedt S, Eichenlaub M, et al. · Diabetes Care · 2025Comparative Study
- Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems.
Hanson K, Kipnes M, Tran H · J Diabetes Sci Technol · 2024Comparative Study, Multicenter Study
- Discrepancies between current displayed and auto-logged glucose values in FreeStyle Libre 3: Implications for clinical interpretation.
Witthauer L, Mendez C, Garcia-Tirado J, et al. · Diabetes Obes Metab · 2025
- Accuracy of FreeStyle Libre 3 During Moderate-Intensity Continuous Aerobic Exercise at Different Phases of the Menstrual Cycle in Females with Type 1 Diabetes.
Cuerda-Del Pino A, Laguna Sanz AJ, Díez JL, et al. · Diabetes Technol Ther · 2025Clinical Trial, Research Support, Non-U.S. Gov't
- Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.
Wilmot EG, Ajjan RA, Cheah YS, et al. · BMJ Open · 2025Clinical Trial Protocol
- Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design.
Alva S, Bhargava A, Bode B, et al. · J Diabetes Sci Technol · 2026Multicenter Study, Research Support, Non-U.S. Gov't
- Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes.
Eichenlaub M, Waldenmaier D, Wehrstedt S, et al. · J Diabetes Sci Technol · 2026Comparative Study
- Erratum for "Accuracy of the Freestyle Libre 3 Continuous Glucose Monitoring System in Hypo- and Euglycemic Cats".
J Vet Intern Med · 2025Published Erratum
- Continuous Glucose Monitoring in Children and Adolescents with Congenital Adrenal Hyperplasia.
Dubinski I, Bechtold-Dalla Pozza S, Debor B, et al. · J Clin Res Pediatr Endocrinol · 2023Observational Study
Other devices of this type
Also filed under product code QBJ.
- Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 510(k) 2026
- Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · De Novo 2023
- Dexcom G7 15 Day Continuous Glucose Monitoring SystemDexcom, Inc. · 510(k) 2025
- FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.